by Sanger sequencing, also known as chain termination sequencing, refers to a method of DNA sequencing developed by Frederick Sanger in 1977. It helps in determining the precise order of nucleotides in a DNA or RNA strand. Sanger sequencing provides an economical and accurate method of reading long strands of nucleotides, and remains a gold standard technique for targeted small-scale DNA sequencing tasks. It finds wide application in DNA fingerprinting, diagnostic tests, paternity testing, forensic biology, and targeted resequencing studies.
The global Sanger sequencing market is estimated to be valued at US$ 10,130.6 Mn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Global Sanger Sequencing Market are Eurofins Scientific, CeMIA, Fasteris SA, GENEWIZ, GenHunter Corporation, GenScript, LGC Biosearch Technologies, Nucleics, Quintara Biosciences, SciGenom Labs Pvt. Ltd, StarSEQ GmbH, Thermo Fisher Scientific Inc., QIAGEN, Promega Corporation, and Source BioScience. The key opportunities in the market include growing applications of Sanger sequencing in genomics research and clinical diagnostics. Several market players are focusing on geographical expansion strategies through partnerships, collaborations and new laboratory establishments across Asian and African countries to tap potential growth opportunities.
Market Drivers
The global Sanger sequencing market is primarily driven by increasing adoption of personalized medicine and growing consumer awareness about genetic disorders, coupled with decreasing cost of DNA sequencing. Sanger sequencing still remains the preferred technique for targeted small-scale sequencing applications including DNA fingerprinting, chain-termination sequencing, polymerase chain reaction (PCR), and DNA fragment analysis. Other factors such as technological advancements to improve accuracy and throughput of Sanger sequencing, and growing R&D investments by pharmaceutical companies and research institutions are also expected to boost the market growth during the forecast period.
PEST Analysis:
Political: Government regulations and policies including concerning research approvals, genomic data protection, sequencing technology adoption etc. can impact market growth.
Economic: Changes in global and regional economic conditions influencing research funding, healthcare spending, and industry investments into sequencing products and services.
Social: Advancement in precision medicine driving demand for sequencing applications in disease diagnosis and management. Increasing awareness and acceptance of genomic testing among population.
Technological: Continued advancement in sequencing platforms and data analysis softwares leading to higher throughput, lower costs and improved analytical capabilities enabling wider adoption across life science research and clinical practice. Development of long read and single molecule sequencing technologies have expanded applications.
The global Sanger sequencing market in terms of value is majorly concentrated in North America. Growing genomics research in the United States supported by strong government funding for sequencing projects has boosted adoption of Sanger sequencing techniques in the region. Significant opportunities also exist in Asia Pacific nations like China and India driven by increasing genomics research investments and growing biotechnology industries.
The fastest growing regional market for Sanger sequencing is likely to be Asia Pacific over the forecast period. Rising focus on precision medicine and population genomics-backed initiatives coupled with expanding biotechnology capabilities point towards increasing sequencing demand across China, Japan and India. Strengthening academic and industry collaborations aimed at genomic research and clinical applications are accelerating Asia Pacific growth.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research.
2. We have leveraged AI tools to mine information and compile it.
